BROCHURES / DOCUMENTATION
APPLICATION NOTES
SCIENTIFIC PUBLICATIONS
You are researching: Prostate Cancer
Inducend Pluripotent Stem Cells (IPSCs)
Drug Discovery
Cancer Cell Lines
Cell Type
Tissue and Organ Biofabrication
Skin Tissue Engineering
Drug Delivery
Biological Molecules
Solid Dosage Drugs
Stem Cells
Personalised Pharmaceuticals
All Groups
- Biomaterials & Bioinks
- Application
- Bioelectronics
- Biomaterial Processing
- Tissue Models – Drug Discovery
- Industrial
- Drug Discovery
- In Vitro Models
- Robotics
- Electronics – Robotics – Industrial
- Medical Devices
- Tissue and Organ Biofabrication
- Drug Delivery
- Skin Tissue Engineering
- Vascularization
- Nerve – Neural Tissue Engineering
- Meniscus Tissue Engineering
- Heart – Cardiac Patches Tissue Engineering
- Adipose Tissue Engineering
- Trachea Tissue Engineering
- Ocular Tissue Engineering
- Intervertebral Disc (IVD) Tissue Engineering
- Muscle Tissue Engineering
- Liver tissue Engineering
- Cartilage Tissue Engineering
- Bone Tissue Engineering
- BioSensors
- Personalised Pharmaceuticals
- Review Paper
- Printing Technology
- Biomaterial
- Thermoplastics
- Non-cellularized gels/pastes
- Poly(vinyl alcohol) (PVA)
- PEDOT
- Jeffamine
- Polyethylene
- SEBS
- Carbopol
- Epoxy
- poly (ethylene-co -vinyl acetate) (PEVA)
- Poly(itaconate-co-citrate-cooctanediol) (PICO)
- Poly(N-isopropylacrylamide) (PNIPAAm)
- Mineral Oil
- poly(octanediol-co-maleic anhydride-co-citrate) (POMaC)
- Poly(Oxazoline)
- Poly(trimethylene carbonate)
- 2-hydroxyethyl) methacrylate (HEMA)
- Zein
- Acrylamide
- Pluronic – Poloxamer
- Polyisobutylene
- Paraffin
- Silicone
- Konjac Gum
- Polyphenylene Oxide
- Ionic Liquids
- Polyvinylpyrrolidone (PVP)
- Gelatin-Sucrose Matrix
- Salt-based
- Chlorella Microalgae
- Acrylates
- Poly(Vinyl Formal)
- 2-hydroxyethyl-methacrylate (HEMA)
- Phenylacetylene
- Magnetorheological fluid (MR fluid – MRF)
- Salecan
- Micro/nano-particles
- Biological Molecules
- Bioinks
- Collagen
- Elastin
- Heparin
- Gelatin
- Matrigel
- Gellan Gum
- Methacrylated Chitosan
- Methacrylated hyaluronic acid (HAMA)
- Pectin
- Silk Fibroin
- Pyrogallol
- Xanthan Gum
- Fibrinogen
- Fibrin
- Paeoniflorin
- Fibronectin
- (2-Hydroxypropyl)methacrylamide (HPMA)
- Methacrylated Collagen (CollMA)
- Carrageenan
- Glucosamine
- Chitosan
- Glycerol
- Poly(glycidol)
- Alginate
- Agarose
- Gelatin-Methacryloyl (GelMA)
- methacrylated chondroitin sulfate (CSMA)
- Cellulose
- Novogel
- Hyaluronic Acid
- Peptide gel
- Methacrylated Silk Fibroin
- Polyethylene glycol (PEG) based
- α-Bioink
- Ceramics
- Decellularized Extracellular Matrix (dECM)
- Metals
- Solid Dosage Drugs
- Bioprinting Technologies
- Bioprinting Applications
- Cell Type
- Stem Cells
- Spheroids
- Meniscus Cells
- Synoviocytes
- Keratinocytes
- Skeletal Muscle-Derived Cells (SkMDCs)
- Neurons
- Macrophages
- Human Trabecular Meshwork Cells
- Endothelial
- CardioMyocites
- Melanocytes
- Retinal
- Chondrocytes
- Embrionic Kidney (HEK)
- Corneal Stromal Cells
- Fibroblasts
- β cells
- Myoblasts
- Pericytes
- Hepatocytes
- Cancer Cell Lines
- Bacteria
- Articular cartilage progenitor cells (ACPCs)
- Tenocytes
- Osteoblasts
- Monocytes
- Mesothelial cells
- Epithelial
- Neutrophils
- Adipocytes
- Human Umbilical Vein Endothelial Cells (HUVECs)
- Organoids
- Institution
- ETH Zurich
- Hallym University
- Nanjing Medical University
- University of Bordeaux
- Innsbruck University
- Nanyang Technological University
- National Institutes of Health (NIH)
- Ningbo Institute of Materials Technology and Engineering (NIMTE)
- KU Leuven
- Politecnico di Torino
- Utrecht Medical Center (UMC)
- Rizzoli Orthopaedic Institute
- Queen Mary University
- Veterans Administration Medical Center
- University of Manchester
- University of Bucharest
- Royal Free Hospital
- Hong Kong University
- University of Barcelona
- Chinese Academy of Sciences
- University of Nottingham
- University of Geneva
- SINTEF
- Rice University
- Trinity College
- Novartis
- University of Central Florida
- Hefei University
- Chalmers University of Technology
- Karlsruhe institute of technology
- University of Freiburg
- Helmholtz Institute for Pharmaceutical Research Saarland
- AO Research Institute (ARI)
- Shanghai University
- Univerity of Hong Kong
- University of Toronto
- Brown University
- University of Wurzburg
- Technical University of Dresden
- University of Nantes
- Montreal University
- Institute for Bioengineering of Catalonia (IBEC)
- University of Michigan – School of Dentistry
- Myiongji University
- Harbin Institute of Technology
- University of Amsterdam
- University of Tel Aviv
- University of Applied Sciences Northwestern Switzerland
- Anhui Polytechnic
- Bayreuth University
- Aschaffenburg University
- University of Michigan, Biointerfaces Institute
- Abu Dhabi University
- Jiao Tong University
- Ghent University
- Chiao Tung University
- Sree Chitra Tirunal Institute
- University of Sheffield
- National University of Singapore
- CIC biomaGUNE
- Kaohsiung Medical University
- DTU – Technical University of Denmark
- Adolphe Merkle Institute Fribourg
- Halle-Wittenberg University
- Baylor College of Medicine
- INM – Leibniz Institute for New Materials
- National Yang Ming Chiao Tung University
- Zurich University of Applied Sciences (ZHAW)
- Innotere
- L'Oreal
- Tiangong University
AUTHOR
Title
Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer
[Abstract]
Year
2021
Journal/Proceedings
Proceedings of the National Academy of Sciences
Reftype
Groups
AbstractMetastatic, castration-resistant prostate cancer (mCRPC) is an advanced prostate cancer with limited therapeutic options and poor patient outcomes. To investigate whether multitargeted kinase inhibitors (KIs) represent an opportunity for mCRPC drug development, we applied machine learning{textendash}based functional screening and identified two KIs, PP121 and SC-1, which demonstrated strong suppression of CRPC growth in vitro and in vivo. Furthermore, we show the marked ability of these KIs to improve on standard-of-care chemotherapy in both tumor response and survival, suggesting that combining multitargeted KIs with chemotherapy represents a promising avenue for mCRPC treatment. Overall, our findings demonstrate the application of a multidisciplinary strategy that blends bench science with machine-learning approaches for rapidly identifying KIs that result in desired phenotypic effects.Castration-resistant prostate cancer (CRPC) is an advanced subtype of prostate cancer with limited therapeutic options. Here, we applied a systems-based modeling approach called kinome regularization (KiR) to identify multitargeted kinase inhibitors (KIs) that abrogate CRPC growth. Two predicted KIs, PP121 and SC-1, suppressed CRPC growth in two-dimensional in vitro experiments and in vivo subcutaneous xenografts. An ex vivo bone mimetic environment and in vivo tibia xenografts revealed resistance to these KIs in bone. Combining PP121 or SC-1 with docetaxel, standard-of-care chemotherapy for late-stage CRPC, significantly reduced tibia tumor growth in vivo, decreased growth factor signaling, and vastly extended overall survival, compared to either docetaxel monotherapy. These results highlight the utility of computational modeling in forming physiologically relevant predictions and provide evidence for the role of multitargeted KIs as chemosensitizers for late-stage, metastatic CRPC.All study data are included in the article and/or supporting information.
AUTHOR
Year
2021
Journal/Proceedings
Journal of Nuclear Medicine
Reftype
Groups
AbstractRadium 223 (223Ra) is an α-emitter approved for the treatment of bone metastatic prostate cancer (PCa), which exerts direct cytotoxicity towards PCa cells near the bone interface, whereas cells positioned in the core respond poorly, due to short α-particle penetrance. β1 integrin (β1I) interference has been shown to increase radiosensitivity and significantly enhance external beam radiation efficiency. We hypothesized that targeting β1I would improve 223Ra outcome. We tested the effect of combining 223Ra and anti-β1I antibody treatment in PC3 and C4-2B PCa cell models expressing high and low β1I levels, respectively. In vivo tumor growth was evaluated through bioluminescence. Cellular and molecular determinants of response were analyzed by ex vivo three-dimensional imaging of bone lesions, proteomic analysis and further confirmed by computational modeling and in vitro functional analysis in tissue-engineered bone mimetic systems. Interference with β1I combined with 223Ra reduced PC3 cell growth in bone and significantly improved overall mouse survival, while no change was achieved in C4-2B tumors. Anti-β1I treatment decreased PC3 tumor cell mitosis index and spatially expanded 223Ra lethal effects two-fold, in vivo and in silico. Regression was paralleled by decreased expression of radio-resistance mediators. Targeting β1I significantly improves 223Ra outcome and points towards combinatorial application in PCa tumors with high β1I expression.